Stay updated with breaking news from Cor Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
22.08.2022 - WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) - CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on lead candidate baxdrostat as part of a poster presentation at the upcoming European Society ... Seite 1
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on...
WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on...
11.08.2022 - WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) - CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other ... Seite 1
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension ... | August 8, 2022